Abstract
To review the potential role of stem cells in treating degenerative disc disease of the intervertebral disc (IVD). A review was performed of articles from the Medline database concerning stem cells and degenerative disc disease (DDD). To discuss the data, the papers were classified as: review, in vitro, experimental, and clinical. The currently available treatments were basically for symptom reduction, not to revert the IVD degenerative process. The use of mesenchymal stem cells (MSC) is being proposed as an option of treatment for DDD. In vitro studies have shown that the MSC are able to differentiate into NP cells and that the MSC also reduce the inflammatory levels of the degenerated IVD. Besides, experimental studies demonstrated that the MSC remained viable when injected into the IVD, and that they were able to regenerate partially from the degenerated IVD and its structure. The few clinical studies found in the literature presented diverging results. The use of MSC is being widely studied and shows promising results for the treatment of DDD. Although many advances are being achieved in studies in vitro and experimental, there is a lack of clinical studies to prove the role of MSC in DDD management. Keywords: Stem cells; Intervertebral disc degeneration; Spine; Mesenchymal stem cells; Intervertebral disc. RESUMO Revisar o potencial papel das células-tronco para o tratamento de doença degenerativa do disco intervertebral (IVD). Foi realizada uma revisão dos trabalhos da base de dados Medline em relação a células-tronco e doença degenerativa discal (DDD). Para fins de discussão dos dados, os trabalhos foram divididos em: revisão, in vitro, experimentais e clínicos. Os tratamentos disponíveis atualmente focam basicamente na redução dos sintomas, e não na reversão do processo degenerativo do DIV. O uso de células-tronco mesenquimais (CTM) vem sendo proposto como uma opção de tratamento para DDD. Estudos in vitro demonstraram que as CTM são capazes de se diferenciarem em células do NP e que as CTM também diminuem os níveis inflamatórios do DIV degenerado. Além disso, estudos experimentais demonstraram que as CTM permaneciam viáveis quando injetadas no DIV e que eram capazes de regenerar parcialmente do DIV degenerado e sua estrutura. Os poucos estudos clínicos presentes na literatura apresentam resultados divergentes. O uso de CTM esta sendo amplamente estudado e mostra resultados promissores para o tratamento da DDD. Embora muitos avanços venham sendo alcançados em estudos in vitro e experimentais, ainda faltam estudos clínicos para comprovar o papel das CTM no manejo da DDD. Descritores: Células-tronco; Degeneração do disco intervertebral; Coluna vertebral; Células-tronco Mesenquimais; Disco intervertebral. RESUMEN Revisar el papel potencial de las células madre en el tratamiento de la enfermedad degenerativa del disco intervertebral (IVD). Se realizó una revisión de los artículos de la base de datos Medline sobre células madre y la enfermedad degenerativa del disco (DDD). Para fines de discusión de los datos, los trabajos se dividieron en: revisión, in vitro, experimentales y clínicos. Los tratamientos disponibles actualmente enfocan básicamente la reducción de los síntomas, y no la reversión del proceso degenerativo del IVD. El uso de células madre mesenquimales (MSC) se propone como una opción de tratamiento para DDD. Estudios in vitro demostraron que las MSC son capaces de diferenciarse en células NP y que las MSC también reducen los niveles inflamatorios de la IVD degenerado. Además, estudios experimentales demostraron que las MSC se mantuvieron viables cuando inyectadas en el IVD y que eran capaces de regenerarse parcialmente del IVD degenerado y su estructura. Los pocos estudios clínicos presentes en la literatura presentan resultados divergentes. El uso de MSC se está estudiando ampliamente y muestra resultados prometedores en el tratamiento de la DDD. Aunque se hayan logrado muchos avances en estudios in vitro y experimentales, aún faltan estudios clínicos para comprobar el papel de las MSC en el manejo de la DDD. Descriptores: Células Madre; Degeneración del disco intervertebral; Columna vertebral; Células madre mesenquimales; Disco intervertebral. INTRODUCTION Degenerative disc disease (DDD) is a common and natural process in the human spine. This degeneration occurs progressively and can affect the biomechanics, stability, and neurological function of the spine 1 . In the United States (US) almost 300.000 surgeries are performed every year due to DDD, with the costs related to the surgical procedures rising to 50 billion dollars annually 2 . Overall, 1.5 million disc surgeries are performed worldwide every year 3 . Annually, approximately 5 of 1000 persons will present sciatica due to disc disorders 4 , which are the major cause of chronic low-back pain in the modern world 5 . Nowadays, degeneration of the intervertebral disc (IVD) is regarded as an irreversible phenomenon. The treatment options involve basically non-surgical (physical therapy, nerve root blocks) and surgical strategies (disc excision and arthrodesis), which are effective only in symptomatic relief and may actually accelerate the degenerative process in adjacent levels 6 . Recent studies demonstrated the potential of stem cell treatment to regenerate or repopulate the degenerated IVD 7-9 . The goal of this study is to review the potential of stem cells as a treatment option for DDD, discussing the actual role of the stem cell treatment. The human spine is composed by 23 IVD that separate the vertebrae and provide flexibility. They account for 20 to 30% of the length of the spine and increase in size on progression from the cervical to the lumbar spine 10 . In addition to flexibility the IVD have the function of stability and support loads during exercise. The IVD structure consists basically in a central part called the nucleus pulposus derived from notochord, which is surrounded by the annulus fibrosus derived from mesenchymal tissue 10 . The nucleus pulposus (NP) is rich in proteoglycan and water whereas the annulus fibrosus is rich in collagen, especially type I, II, VI and IX 11,12 . The composition of the IVD varies with the level of the spine, the collagen content in the nucleus being highest in the cervical discs and lowest in the lumbar discs, whereas the proteoglycan content shows the opposite trend 13 . In the mature NP, the proteoglycan aggregates are important to retain water and restricting the water flux influences the response of the tissue to loads delivered in the spine 11 . With ageing principally in the nucleus there is a decrease of proteoglycan aggregates and an increase of nonaggregating aggrecan because of proteolytic degradation 14,15 . Thus, with age the ability of resist compressive loading declines. In the annulus fibrosus the collagen fibrils are oriented in sheets around the NP. The key function of this structure is to retain the NP, taking up and distributing the load exerted by this tissue during various types of exercise 11 . During life many changes occur in the composition of the extracellular matrix including notochordal cell loss, mesenchymal cell senescence, loss of the vasculature and calcification of the vertebral endplates, which alter or decrease the synthetic capabilities of the disc cells 10 . Nuclear cell density decreases with age throughout life, whereas annular cellularity reaches a plateau after the age of 50 years 16 . The normal turnover capability is impaired in the disc matrix and degeneration products accumulate 10 . The IVD degeneration and its structural changes result from this continuum catabolism occurring in the extracellular matrix associated with the incapacity of replace the impaired collagen fibers and aggrecan with new molecules during life. The IVD appears incapable of intrinsic repair in the adult, but it is the dream of physicians to be able to induce such biologic repair 17 . Nowadays, surgical and non-surgical therapies to manage IVD degeneration focus only on symptom relief. In recent years, as the understanding of the molecular and cellular events involved in disc degeneration has improved, the idea of manipulating the cellular content of the disc to achieve a beneficial outcome has grown 6,18 . One treatment option is the use substances in order to stimulate the existing disc cells to increase production of proteoglycan. However, due to the relative accelularity of the degenerated disc it may not be sufficient to achieve a good result. An option for that issue is to introduce in the degenerated disc cells capable of producing appropriate matrix in an attempt to recover the biomechanical properties of the disc 6 . Nishimura et al. 19 performed the transplantation of autologous NP tissue into denucleated rat discs, where it was shown to slow the progression of degeneration. However, this cell source has practical limitations in the clinical setting due to the necessity of damaging an adjacent disc, likely inducing degeneration in this level. By contrast, adult mesenchymal stem cells (MSC) are easily procured by bone marrow aspiration, and are more capable of adapting successfully to the environment of the disc and therefore of achieving a differentiated state appropriate for long-term matrix synthesis 6 . MSC are undifferentiated, multipotent cells that have the ability to differentiate into a number of cell types, including bone, cartilage, fat, muscle and tendons, depending on the environment and biologic signals provided. It has already been established that MSC can be pushed into chondrogenic or perhaps even discogenic pathways and are capable of expressing aggrecan and Type II collagen in large quantities 20 . Another advantage is the fact that MSC can be obtained from many autologous sources including bone marrow and fat without significant morbidity or immunogenic response and can be easily expanded in cultures 21 . It was already known that MS